Q-omics provides the consensus-scored BMS1P20 profile across patient tissues and cancer cell-line models. BMS1P20 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, BMS1P20 is differentially expressed in 11, with the highest sampling consensus in LIHC. Additionally, BMS1P20 RNA expression shows 19,090 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight UCS, LIHC, and ACC as cancer lineages where BMS1P20 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BMS1P20 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BMS1P20 survival associations across molecular data types. BMS1P20 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BMS1P20 RNA expression–survival associations across cancer types. High BMS1P20 expression shows unfavorable associations in ACC, LIHC, COAD and KIRP, but favorable associations in UCS and READ. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .003). Together, the overview and detailed table identify UCS as the clearest survival context for BMS1P20 RNA expression.
This table summarizes BMS1P20 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for BMS1P20. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BMS1P20 shows lower tumor expression in KICH and higher tumor expression in LIHC, LUAD, BLCA, LUSC and COAD. The LIHC box plot shows higher BMS1P20 RNA expression in tumor versus normal tissue (log2 FC = +0.794, t-test p < 0.001).
This table shows molecular features associated with BMS1P20 in patient tissues and cancer cell lines. In patient samples, BMS1P20 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
